In short
There is currently 1 ongoing clinical trial focused on pigmentary glaucoma, investigating the effectiveness of citicoline eye drops in preserving vision. This trial is being conducted across multiple European countries and aims to determine whether this treatment can slow the progression of vision loss in patients with open-angle glaucoma and related conditions.
Clinical trial locations
- Belgium
- France
- Greece
- Hungary
- Italy
- Poland
- Spain
Study on the Effectiveness of Citicoline Eye Drops for Visual Field Preservation in Patients with Open Angle Glaucoma
This clinical trial is examining whether citicoline eye drops can help preserve vision in people with open-angle glaucoma, including related forms such as pseudoexfoliation and pigmentary glaucoma. The study compares citicoline eye drops to placebo eye drops over a three-year period to determine if there is a difference in how vision changes over time.
Main inclusion criteria: To participate in this study, you must be at least 18 years old and have been diagnosed with open-angle glaucoma, pseudoexfoliation glaucoma, or pigmentary glaucoma. Your vision must be correctable to at least 0.5 in the eye being studied, and the pressure inside your eye must be controlled at 18 mmHg or less. Your peripheral vision should not be worse than -12 dB as measured by visual field tests. You must also have specific changes in your optic nerve that are characteristic of glaucoma. Women who are able to become pregnant must agree to use highly effective birth control during the study and for 90 days after treatment ends. Written consent to participate is required.
Main exclusion criteria: You cannot participate if you do not have open-angle glaucoma, if your condition is not worsening, or if you are not being treated according to the best clinical practices for managing this condition. The study also excludes patients outside the specified age range and those who belong to vulnerable populations not included in the study design.
Focus and goal: The main goal of this study is to determine whether citicoline eye drops can better preserve the visual field compared to placebo. Throughout the three years, participants will attend regular check-ups to monitor their eye health and the progression of their condition. The researchers will measure changes in peripheral vision and assess the thickness of certain layers in the retina using a technique called Optical Coherence Tomography. The study team will randomly assign participants to receive either citicoline eye drops at a 2% concentration or placebo eye drops containing hyaluronic acid and other inactive ingredients.
Investigational drug: The treatment being tested is citicoline, administered as eye drops at a 2% concentration. Citicoline is thought to support nerve cell health in the eye and potentially protect the optic nerve from damage. It is classified as a neuroprotective agent and is being investigated for its ability to slow the progression of vision loss in patients with glaucoma.
Summary
Currently, there is one clinical trial available for patients with pigmentary glaucoma, focusing on the potential benefits of citicoline eye drops. This trial is being conducted across seven European countries: Spain, Belgium, France, Greece, Italy, Hungary, and Poland, making it accessible to a wide range of patients across Europe. The study represents an important effort to find new ways to protect vision in people with this condition, as it investigates whether neuroprotective treatment can slow the progression of vision loss over a three-year period. The multi-country approach ensures diverse patient participation and strengthens the reliability of the findings.
